Navigation Links
Gen-Probe to Webcast Two Upcoming Investor Presentations

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the Oppenheimer 20th Annual Healthcare Conference in New York on November 3, 2009 at approximately 2:10 p.m. Eastern time, and at the Lazard Capital Markets 6th Annual Healthcare Conference in New York on November 18, 2009 at approximately 9 a.m. Eastern time. The presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at The webcasts will be available for 30 days following the events.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,200 people. For more information, go to

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended June 30, 2009, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.


    Paula Izidoro
    Investor Relations

SOURCE Gen-Probe Incorporated

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
2. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
3. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
4. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. Beckman Coulter Announces Conference Call and Webcast of Accompanying Slides in Conjunction With Third Quarter 2009 Earnings
7. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast
9. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
10. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 ... tecnología para cuchillas de precisión, develó hoy ... de identidad de marca. El nuevo logo ... diseño y la ingeniería de productos con ... diferencia". ...
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Florida Hospital Tampa is the first health care provider in the region ... , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, for the ... (BMI) of at least 40 to 45 kg, or a BMI of at least 35 ...
(Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
(Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... mark the film for accurate interpretation by the radiologist. The marking utensils are ... from Sacramento, Calif., has found a way to alleviate this problem. , He ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announced it has been awarded a fixed price per sprint agile development contract ... valued at $34 million over five years, provides software engineering, infrastructure, as well ...
Breaking Medicine News(10 mins):